|
WO2021046270A1
|
|
Detection of chlamydia trachomatis nucleic acid variants
|
|
WO2021041537A1
|
|
Receptacle transport carriers
|
|
WO2021041056A1
|
|
Compositions, methods and kits for detecting treponema pallidum
|
|
WO2021003331A1
|
|
Oligonucleotides for use in determining the presence of trichomonas vaginalis in a sample
|
|
WO2020226969A2
|
|
Receptacle transport system for an analytical system
|
|
WO2020226897A1
|
|
System and method for managing liquid waste
|
|
WO2020197987A1
|
|
Compositions and methods for detecting group a streptococcus
|
|
WO2020205264A1
|
|
Disposable pipette tip management
|
|
US2020282403A1
|
|
Carrier for holding a plurality of multi-receptacle units
|
|
WO2020154513A1
|
|
Detection of drug-resistant mycoplasma genitalium
|
|
TW202030333A
|
|
Compositions and methods for detecting plasmodium species nucleic acid
|
|
WO2020086546A1
|
|
Compositions and methods for amplifying, detecting or quantifying human polyomavirus bk virus
|
|
WO2020072409A1
|
|
Compositions and methods for amplifying or detecting varicella-zoster virus
|
|
CA3112651A1
|
|
Compositions and methods for detecting bordetella pertussis and bordetella parapertussis nucleic acid
|
|
AU2019324196A1
|
|
Compositions and methods for detecting bacterial nucleic acid and diagnosing bacterial vaginosis
|
|
CA3107043A1
|
|
Compositions and methods for amplifying, detecting or quantifying human cytomegalovirus
|
|
AU2019286648A1
|
|
Compositions and methods for detecting group B Streptococcus nucleic acid
|
|
WO2020033557A1
|
|
Compositions, methods and kits for detecting mycoplasma genitalium
|
|
AU2019314449A1
|
|
Compositions and methods for detecting nucleic acids of Epstein-Barr virus
|
|
CA3105684A1
|
|
Methods and systems for detecting and quantifying nucleic acids
|
